[Evaluation of hepatic arterial infusion chemotherapy for gastric cancer]. 1996

T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
Dept. of Surgery, Himeji St. Mary's Hospital.

Hepatic arterial infusion chemotherapy (HAIC) using implantable reservoir was performed for liver metastases of gastric cancer and the therapeutic effects were evaluated. A catheter was placed in the hepatic artery via left subclavian artery or by direct insertion at laparotomy. Cisplatin, adriamycin and 5-FU were administered. The liver metastases of gastric cancer without unresectable primary tumors and hepatectomy were divided into two groups, 16 HAIC cases (11 synchronous, 5 metachronous metastases) and 23 systemic chemotherapeutic cases (10 synchronous, 13 metachronous metastases). As a result, HAIC revealed a 62.5% response rate. The 50% survival period was 395 days for HAIC, and it was significantly prolonged compared with 198 days for systemic chemotherapy (p < 0.01). But 4 among 10 cases responding to HAIC showed subsequent extrahepatic spread of the disease. Treatment of these extra-hepatic lesions is difficult.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
November 2009, Gan to kagaku ryoho. Cancer & chemotherapy,
T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
July 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
July 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
October 2001, Gan to kagaku ryoho. Cancer & chemotherapy,
T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
November 2002, Gan to kagaku ryoho. Cancer & chemotherapy,
T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
October 2003, Gan to kagaku ryoho. Cancer & chemotherapy,
T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
January 1984, The Japanese journal of surgery,
T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
July 1984, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
February 1994, Histopathology,
T Uemura, and S Kawasaki, and H Kawai, and M Suga, and S Maruyama, and J Otani, and S Morisue, and K Yoshizane, and Y Morokoshi, and M Yamamoto, and M Soda
January 1985, Diagnostic cytopathology,
Copied contents to your clipboard!